New approaches from nanomedicine for treating leishmaniasis

New approaches from nanomedicine for treating leishmaniasis

Author Gutierrez, Victor Google Scholar
Seabra, Amedea B. Autor UNIFESP Google Scholar
Reguera, Rosa M. Google Scholar
Khandare, Jayant Google Scholar
Calderon, Marcelo Google Scholar
Abstract Leishmaniasis, a vector-borne disease caused by obligate intramacrophage protozoa, threatens 350 million people in 98 countries around the world. There are already 12 million infected people worldwide and two million new cases occur annually. Leishmaniasis has three main clinical presentations: cutaneous (CL), mucosal (ML), and visceral (VL). It is considered an opportunistic, infectious disease and the HIV-leishmaniasis correlation is well known. Antimonial compounds are used as first-line treatment drugs, but their toxicity, which can be extremely high, leads to a number of undesirable side effects and resultant failure of the patients to adhere to treatment. There is also a reported increase in Leishmania sp. resistance to these drugs. Nanotechnology has emerged as an attractive alternative because of its improved bioavailability and lower toxicity, and other characteristics that help to relieve the burden of this disease. In this review we will present some of the recent advances in the nanotechnological research regarding the treatment of leishmaniasis. The preclinical results regarding the approaches for a biomedical treatment of the disease have been encouraging, but further efforts will still be necessary for this therapy to have greater clinical applicability in humans.
Keywords Liposomal Amphotericin-B
Solid-Lipid Nanoparticles
Host Immune-Response
Nitric-Oxide Donor
Cutaneous Leishmaniasis
Visceral Leishmaniasis
In-Vitro
Delivery-Systems
Dna Vaccination
Dendritic Cells
Language English
Sponsor Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Deutsche Forschungsgemeinschaft (DFG)/German Research Foundation [SFB1112]
Bundesministerium fur Bildung und Forschung (BMBF) through the NanoMatFutur award [13N12561]
Helmholtz Virtual Institute, Multifunctional Biomaterials for Medicine
Freie Universitat Berlin Focus Area Nanoscale
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Grant number FAPESP: 2012/17053-7
MCTI/CNPq: PI12/00104
CYTED: 214RT0482
Date 2016
Published in Chemical Society Reviews. Cambridge, v. 45, n. 1, p. 152-168, 2016.
ISSN 0306-0012 (Sherpa/Romeo, impact factor)
Publisher Royal Soc Chemistry
Extent 152-168
Origin http://dx.doi.org/10.1039/c5cs00674k
Access rights Closed access
Type Revisão
Web of Science ID WOS:000367250700008
URI http://repositorio.unifesp.br/handle/11600/49687

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account